U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Leiter's Enterprises, Inc. dba Leiter's - 477540 - 05/29/2018
  1. Warning Letters

CLOSEOUT LETTER

Leiter's Enterprises, Inc. dba Leiter's MARCS-CMS 477540 —

Recipient:
Leiter's Enterprises, Inc. dba Leiter's

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
Division of Pharmaceutical Quality Operations IV
19701 Fairchild Road, Irvine, CA 92612
Telephone: (949) 608-2900
Fax: (949) 608-4417

May 29, 2018

Robin Smith Hoke, President and CEO
Leiter’s Enterprises, Inc. dba Leiter’s
17 Great Oaks Blvd.
San Jose, CA 95119-1359

Dear Ms. Hoke:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (ref: WL# 477540), dated February 29, 2016. From June 7, 2017, to June 15, 2017, an FDA investigator conducted a reinspection of your facility, Leiter’s Enterprises, Inc. dba Leiter’s, located at 17 Great Oaks Blvd., San Jose, CA 95119-1359. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV 

Back to Top